Skip to main content

Pleiotropic Effects of Statins

Evidence for Benefits Beyond LDL-Cholesterol Lowering

American Journal of Cardiovascular Drugs volume 10, pages 3–9 (2010)Cite this article

Abstract

Evidence is mounting that 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) have a number of pleiotropic effects over and above their lipid-lowering properties in patients with cardiovascular disease and heart failure. In addition to lowering low-density lipoprotein cholesterol and triglyceride levels, several studies have shown statins to improve survival and reduce the risk of major cardiovascular events in patients without established cardiovascular disease but with cardiovascular risk factors. Statins have also been shown to have beneficial effects, including a reduction in all-cause mortality, in patients with ischemic and non-ischemic congestive heart failure, and have been associated with a reduced incidence of atrial fibrillation. Furthermore, statins have been associated with improvements in renal function in patients with pre-existing renal disease or the prevention of new-onset renal dysfunction, as well as improvements in lung function in patients with chronic obstructive pulmonary disease or age-related decline in lung function. The pleiotropic effects of statins appear to result from improvements in endothelial function, a reduction in inflammatory mediators, a decline in the development of atheroma through the stabilization of atheromatous plaques, and the inhibition of cardiac hypertrophy through an antioxidant mechanism. Long-term statin use may reduce morbidity and mortality rates in a broad range of patients, and most patients at high risk of cardiovascular disease may benefit from statin treatment; however, further data are required to demonstrate conclusively whether these trends are truly independent of the lipid-lowering effects of statins.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

49,54 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Table I

References

  1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994 Nov 19; 344 (8934): 1383–9.

  2. Hale LP, Craver KT, Berrier AM, et al. Combination of fosinopril and pravastatin decreases platelet response to thrombin receptor agonist in monkeys. Arterioscler Thromb Vasc Biol 1998 Oct; 18(10): 1643–6.

    PubMed  Article  CAS  Google Scholar 

  3. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998 May 27; 279(20): 1615–22.

    PubMed  Article  CAS  Google Scholar 

  4. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002 Jul 6; 360(9326): 7–22.

    Article  Google Scholar 

  5. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996 Oct 3; 335(14): 1001–9.

    PubMed  Article  CAS  Google Scholar 

  6. Sever PS, Dahlof B, Poulter NR, et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial — Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet 2003 Apr 5; 361(9364): 1149–58.

    PubMed  Article  CAS  Google Scholar 

  7. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995 Nov 16; 333(20): 1301–7.

    PubMed  Article  CAS  Google Scholar 

  8. Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005 Oct 8; 366(9493): 1267–78.

    PubMed  Article  CAS  Google Scholar 

  9. Halcox JP, Deanfield JE. Beyond the laboratory: clinical implications for statin pleiotropy. Circulation 2004 Jun 1; 109 (21 Suppl. 1): II42–8.

    PubMed  Article  Google Scholar 

  10. Beri A, Sural N, Mahajan SB. Non-atheroprotective effects of statins: a systematic review. Am J Cardiovasc Drugs 2009; 9(6): 361–70.

    PubMed  Article  CAS  Google Scholar 

  11. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT). JAMA 2002 Dec 18; 288(23): 2998–3007.

    Article  Google Scholar 

  12. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004 Aug 21–27; 364(9435): 685–96.

    PubMed  Article  CAS  Google Scholar 

  13. Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003 Jun 14; 361(9374): 2005–16.

    PubMed  Article  Google Scholar 

  14. Knopp RH, D’Emden M, Smilde JG, et al. Efficacy and safety of atorvastatin in the prevention of cardiovascular end points in subjects with type 2 diabetes: the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in non-insulin-dependent diabetes mellitus (ASPEN). Diabetes Care 2006 Jul; 29(7): 1478–85.

    PubMed  Article  CAS  Google Scholar 

  15. Nakamura H, Arakawa K, Itakura H, et al. Primary prevention of cardiovascular disease with pravastatin in Japan (MEGA Study): a prospective randomised controlled trial. Lancet 2006 Sep 30; 368(9542): 1155–63.

    PubMed  Article  CAS  Google Scholar 

  16. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008 Nov 20; 359(21): 2195–207.

    PubMed  Article  CAS  Google Scholar 

  17. Sever PS, Poulter NR, Dahlof B, et al. The Anglo-Scandinavian Cardiac Outcomes Trial lipid lowering arm: extended observations 2 years after trial closure. Eur Heart J 2008 Feb; 29(4): 499–508.

    PubMed  Article  CAS  Google Scholar 

  18. Shepherd J, Blauw GJ, Murphy MB, et al. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet 2002 Nov 23; 360(9346): 1623–30.

    PubMed  Article  CAS  Google Scholar 

  19. Shishehbor MH, Hazen SL. Jupiter to earth: a statin helps people with normal LDL-C and high hs-CRP, but what does it mean? Cleve Clin J Med 2009 Jan; 76(1): 37–44.

    PubMed  Article  Google Scholar 

  20. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: metaanalysis of randomised controlled trials. BMJ 2009; 338: b2376.

    PubMed  Article  CAS  Google Scholar 

  21. Fukuta H, Sane DC, Brucks S, et al. Statin therapy may be associated with lower mortality in patients with diastolic heart failure: a preliminary report. Circulation 2005 Jul 19; 112(3): 357–63.

    PubMed  Article  CAS  Google Scholar 

  22. Go AS, Lee WY, Yang J, et al. Statin therapy and risks for death and hospitalization in chronic heart failure. JAMA 2006 Nov 1; 296(17): 2105–11.

    PubMed  Article  CAS  Google Scholar 

  23. Horwich TB, MacLellan WR, Fonarow GC. Statin therapy is associated with improved survival in ischemic and non-ischemic heart failure. J Am Coll Cardiol 2004 Feb 18; 43(4): 642–8.

    PubMed  Article  CAS  Google Scholar 

  24. Khush KK, Waters DD, Bittner V, et al. Effect of high-dose atorvastatin on hospitalizations for heart failure: subgroup analysis of the Treating to New Targets (TNT) study. Circulation 2007 Feb 6; 115(5): 576–83.

    PubMed  Article  CAS  Google Scholar 

  25. Ray JG, Gong Y, Sykora K, et al. Statin use and survival outcomes in elderly patients with heart failure. Arch Intern Med 2005 Jan 10; 165(1): 62–7.

    PubMed  Article  CAS  Google Scholar 

  26. Shah R, Wang Y, Foody JM. Effect of statins, angiotensin-converting enzyme inhibitors, and beta blockers on survival in patients >or = 65 years of age with heart failure and preserved left ventricular systolic function. Am J Cardiol 2008 Jan 15; 101(2): 217–22.

    PubMed  Article  CAS  Google Scholar 

  27. Yamada T, Node K, Mine T, et al. Long-term effect of atorvastatin on neurohumoral activation and cardiac function in patients with chronic heart failure: a prospective randomized controlled study. Am Heart J 2007 Jun; 153(6): 1055 e1–8.

    Article  Google Scholar 

  28. Dickinson MG, Ip JH, Olshansky B, et al. Statin use was associated with reduced mortality in both ischemic and nonischemic cardiomyopathy and in patients with implantable defibrillators: mortality data and mechanistic insights from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Am Heart J 2007 Apr; 153(4): 573–8.

    PubMed  Article  CAS  Google Scholar 

  29. Domanski M, Coady S, Fleg J, et al. Effect of statin therapy on survival in patients with nonischemic dilated cardiomyopathy (from the Beta-blocker Evaluation of Survival Trial [BEST]). Am J Cardiol 2007 May 15; 99(10): 1448–50.

    PubMed  Article  CAS  Google Scholar 

  30. Rinfret S, Behlouli H, Eisenberg MJ, et al. Class effects of statins in elderly patients with congestive heart failure: a population-based analysis. Am Heart J 2008 Feb; 155(2): 316–23.

    PubMed  Article  CAS  Google Scholar 

  31. Kjekshus J, Apetrei E, Barrios V, et al. Rosuvastatin in older patients with systolic heart failure. N Engl J Med 2007 Nov 29; 357(22): 2248–61.

    PubMed  Article  CAS  Google Scholar 

  32. Tavazzi L, Maggioni AP, Marchioli R, et al. Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 2008 Oct 4; 372(9645): 1231–9.

    PubMed  Article  Google Scholar 

  33. Kjekshus J, Pedersen TR, Olsson AG, et al. The effects of simvastatin on the incidence of heart failure in patients with coronary heart disease. J Card Fail 1997 Dec; 3(4): 249–54.

    PubMed  Article  CAS  Google Scholar 

  34. Node K, Fujita M, Kitakaze M, et al. Short-term statin therapy improves cardiac function and symptoms in patients with idiopathic dilated cardiomyopathy. Circulation 2003 Aug 19; 108(7): 839–43.

    PubMed  Article  CAS  Google Scholar 

  35. Fauchier L, Pierre B, de Labriolle A, et al. Antiarrhythmic effect of statin therapy and atrial fibrillation: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 2008 Feb 26; 51(8): 828–35.

    PubMed  Article  CAS  Google Scholar 

  36. Virani SS, Nambi V, Razavi M, et al. Preoperative statin therapy is not associated with a decrease in the incidence of postoperative atrial fibrillation in patients undergoing cardiac surgery. Am Heart J 2008 Mar; 155(3): 541–6.

    PubMed  Article  CAS  Google Scholar 

  37. Adabag AS, Nelson DB, Bloomfield HE. Effects of statin therapy on preventing atrial fibrillation in coronary disease and heart failure. Am Heart J 2007 Dec; 154(6): 1140–5.

    PubMed  Article  CAS  Google Scholar 

  38. McLean DS, Ravid S, Blazing M, et al. Effect of statin dose on incidence of atrial fibrillation: data from the Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI22) and Aggrastat to Zocor (A to Z) trials. Am Heart J 2008 Feb; 155(2): 298–302.

    PubMed  Article  CAS  Google Scholar 

  39. Tonelli M, Isles C, Craven T, et al. Effect of pravastatin on rate of kidney function loss in people with or at risk for coronary disease. Circulation 2005 Jul 12; 112(2): 171–8.

    PubMed  Article  CAS  Google Scholar 

  40. Verma A, Ranganna KM, Reddy RS, et al. Effect of rosuvastatin on C-reactive protein and renal function in patients with chronic kidney disease. Am J Cardiol 2005 Nov 1; 96(9): 1290–2.

    PubMed  Article  CAS  Google Scholar 

  41. Vidt DG, Harris S, McTaggart F, et al. Effect of short-term rosuvastatin treatment on estimated glomerular filtration rate. Am J Cardiol 2006 Jun 1; 97(11): 1602–6.

    PubMed  Article  CAS  Google Scholar 

  42. Sukhija R, Bursac Z, Kakar P, et al. Effect of statins on the development of renal dysfunction. Am J Cardiol 2008 Apr 1; 101(7): 975–9.

    PubMed  Article  CAS  Google Scholar 

  43. Schouten O, Kok NF, Boersma E, et al. Effects of statins on renal function after aortic cross clamping during major vascular surgery. Am J Cardiol 2006 May 1; 97(9): 1383–5.

    PubMed  Article  CAS  Google Scholar 

  44. Tabata M, Khalpey Z, Pirundini PA, et al. Renoprotective effect of preoperative statins in coronary artery bypass grafting. Am J Cardiol 2007 Aug 1; 100(3): 442–4.

    PubMed  Article  CAS  Google Scholar 

  45. Frost FJ, Petersen H, Tollestrup K, et al. Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins. Chest 2007 Apr; 131(4): 1006–12.

    PubMed  Article  CAS  Google Scholar 

  46. Mancini GB, Etminan M, Zhang B, et al. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J Am Coll Cardiol 2006 Jun 20; 47(12): 2554–60.

    PubMed  Article  CAS  Google Scholar 

  47. Alexeeff SE, Litonjua AA, Sparrow D, et al. Statin use reduces decline in lung function: VA Normative Aging Study. Am J Respir Crit Care Med 2007 Oct 15; 176(8): 742–7.

    PubMed  Article  Google Scholar 

  48. Keddissi JI, Younis WG, Chbeir EA, et al. The use of statins and lung function in current and former smokers. Chest 2007 Dec; 132(6): 1764–71.

    PubMed  Article  CAS  Google Scholar 

  49. Brunton LL, Lazo JS, Parker KL. Goodman & Gilman’s The Pharmacological Basis of Therapeutics, 11e. The McGraw-Hill Companies, Inc. 2006.

  50. Briguori C, Visconti G, Focaccio A, et al. Novel approaches for preventing or limiting events (NAPLES) II trial: impact of a single high loading dose of atorvastatin on periprocedural myocardial infarction. J Am Coll Cardiol 2009 Dec 1; 54(23): 2157–63.

    PubMed  Article  CAS  Google Scholar 

  51. Di Sciascio G, Patti G, Pasceri V, et al. Efficacy of atorvastatin reload in patients on chronic statin therapy undergoing percutaneous coronary intervention: results of the ARMYDA-RECAPTURE (Atorvastatin for Reduction of Myocardial Damage During Angioplasty) Randomized Trial. J Am Coll Cardiol 2009 Aug 4; 54(6): 558–65.

    PubMed  Article  Google Scholar 

  52. Biasucci LM, Porto I. Has atorvastatin more than a DUAAL face? Eur Heart J. Epub 2010 Jul 8.

  53. Deanfield JE, Sellier P, Thaulow E, et al. Potent anti-ischaemic effects of statins in chronic stable angina: incremental benefit beyond lipid lowering? Eur Heart J. Epub 2010 May 21.

  54. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001 Apr 4; 285(13): 1711–18.

    PubMed  Article  CAS  Google Scholar 

  55. Wenke K, Meiser B, Thiery J, et al. Simvastatin initiated early after heart transplantation: 8-year prospective experience. Circulation 2003 Jan 7; 107(1): 93–7.

    PubMed  Article  CAS  Google Scholar 

  56. Gibson CM, Pride YB, Hochberg CP, et al. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy. J Am Coll Cardiol 2009 Dec 8; 54(24): 2290–5.

    PubMed  Article  CAS  Google Scholar 

  57. Mora S, Ridker PM. Justification for the Use of Statins in Primary Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) — can C-reactive protein be used to target statin therapy in primary prevention? Am J Cardiol 2006 Jan 16; 97(2A): 33A–41A.

    PubMed  Article  CAS  Google Scholar 

  58. Liao JK, Laufs U. Pleiotropic effects of statins. Annu Rev Pharmacol Toxicol 2005; 45: 89–118.

    PubMed  Article  CAS  Google Scholar 

  59. Martinez-Gonzalez J, Badimon L. Influence of statin use on endothelial function: from bench to clinics. Curr Pharm Des 2007; 13(17): 1771–86.

    PubMed  Article  CAS  Google Scholar 

  60. Anderson TJ, Meredith IT, Yeung AC, et al. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med 1995 Feb 23; 332(8): 488–93.

    PubMed  Article  CAS  Google Scholar 

  61. O’Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation 1997 Mar 4; 95(5): 1126–31.

    PubMed  Article  Google Scholar 

  62. Treasure CB, Klein JL, Weintraub WS, et al. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med 1995 Feb 23; 332(8): 481–7.

    PubMed  Article  CAS  Google Scholar 

  63. Walter DH, Dimmeler S, Zeiher AM. Effects of statins on endothelium and endothelial progenitor cell recruitment. Semin Vasc Med 2004 Nov; 4(4): 385–93.

    PubMed  Article  Google Scholar 

  64. Albert MA, Staggers J, Chew P, et al. The pravastatin inflammation CRP evaluation (PRINCE): rationale and design. Am Heart J 2001 Jun; 141(6): 893–8.

    PubMed  Article  CAS  Google Scholar 

  65. Ridker PM, Rifai N, Clearfield M, et al. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events. N Engl J Med 2001 Jun 28; 344(26): 1959–65.

    PubMed  Article  CAS  Google Scholar 

  66. Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999 Jul 20; 100(3): 230–5.

    PubMed  Article  CAS  Google Scholar 

  67. Ridker PM, Rifai N, Pfeffer MA, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998 Sep 1; 98(9): 839–44.

    PubMed  Article  CAS  Google Scholar 

  68. Crisby M, Nordin-Fredriksson G, Shah PK, et al. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metal-loproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation 2001 Feb 20; 103(7): 926–33.

    PubMed  Article  CAS  Google Scholar 

  69. Huhle G, Abletshauser C, Mayer N, et al. Reduction of platelet activity markers in type II hypercholesterolemic patients by a HMG-CoA-reductase inhibitor. Thromb Res 1999 Sep 1; 95(5): 229–34.

    PubMed  Article  CAS  Google Scholar 

  70. Lee TM, Chou TF, Tsai CH. Association of pravastatin and left ventricular mass in hypercholesterolemic patients: role of 8-iso-prostaglandin f2alpha formation. J Cardiovasc Pharmacol 2002 Dec; 40(6): 868–74.

    PubMed  Article  CAS  Google Scholar 

  71. Maack C, Kartes T, Kilter H, et al. Oxygen free radical release in human failing myocardium is associated with increased activity of rac1-GTPase and represents a target for statin treatment. Circulation 2003 Sep 30; 108(13): 1567–74.

    PubMed  Article  CAS  Google Scholar 

  72. Takemoto M, Node K, Nakagami H, et al. Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. J Clin Invest 2001 Nov; 108(10): 1429–37.

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The author would like to acknowledge Neil Reynolds and Juliane Weber of inScience Communications, a Wolters Kluwer business, who provided medical writing support funded by Pfizer. The author has no conflicts of interest to declare.

Author information

Affiliations

  1. Division of Cardiovascular Medicine, Cardiothoracic Department, University of Pisa, Via Paradisa 2, 56100, Pisa, Italy

    Mario Marzilli

Authors
  1. Mario Marzilli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mario Marzilli.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Marzilli, M. Pleiotropic Effects of Statins. Am J Cardiovasc Drugs 10, 3–9 (2010). https://doi.org/10.2165/1153644-S0-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/1153644-S0-000000000-00000

Keywords

  • Chronic Obstructive Pulmonary Disease
  • Statin
  • Simvastatin
  • Placebo Recipient
  • Statin Therapy